Treatment of psoriasis vulgaris with calcipotriol betamethasone dipropionate combination followed by calcipotriol and assessment of the adjuvant basic use of urea-based emollients

European Journal of Inflammation

Volumn 3, Issue 1, 2005, Pages 37-41

  Vena, G A ^a   Cassano, N ^a,b   Agnusdei, C P ^c   Bellini, M ^c   Calabretta, S ^c   Centofanti, S ^c   Cervadoro, G ^c   Coviello, C ^a   Curia, S ^c   Dattola, S ^c   De Caro, C ^c   Del Brocco, L ^c   Donato, L ^c   Favero, L ^c   Ferrari, A ^c   Gianfaldoni, R ^c   Liguori, G ^c   Loconsole, F ^a   Lopreiato, R ^c   Malara, G ^c   Massimino, S D ^c   Nannipieri, A ^c   Pettinato, M ^c   Postiglione, D ^c   Postorino, C ^c   Pronesti, M E ^c   Provenzano, E ^c   Puglisi Guerra, A ^c   Ricciuti, F ^c   Ruggiero, G ^c   Scudero, A ^c   Spitaleri, S ^c   Armati, F Trinca ^c   Valenti, G ^c   Vernaci, R ^c   Verrina, F ^c   Zagni, G F ^c   Zappala', F ^c   more..

^a UNIVERSITY OF BARI   (Italy)

^b LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^c Italian Grp Study Emollients Psoria   (Italy)

Author keywords

Betamethasone dipropionate; Calcipotriol; Combination product; Emollients; Psoriasis vulgaris; Urea

Indexed keywords

BETAMETHASONE DIPROPIONATE; BETAMETHASONE DIPROPIONATE PLUS CALCIPOTRIOL; CALCIPOTRIOL; EMOLLIENT AGENT; EXCIPIAL U; UNCLASSIFIED DRUG; UREA;

ADULT; ARTICLE; BURNING SENSATION; CLINICAL TRIAL; CREAM; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; KOLMOGOROV SMIRNOV TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OINTMENT; OPEN STUDY; PATIENT COMPLIANCE; PSORIASIS VULGARIS; RATING SCALE; SEQUENTIAL ANALYSIS; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY; TREATMENT OUTCOME;

EID: 20044388727     PISSN: 1721727X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1721727X0500300108     Document Type: Article

References (26)

1. Lange K., B. Kleuser, A. Gysler, M. Bader, C. Maia, C. Scheidereit, et al. 2000. Cutaneous inflammation and proliferation in vitro: differential effects and mode of action of topical glucocorticoids. Skin. Pharmacol. Appl. Skin. Physiol 13:93.
2. Mozzanica N., A. Cattaneo, E. Schmitt, R. Diotti and A.F. Finzi. 1994. Topical calcipotriol for psoriasis - an immunohistologic study. Acta Derm. Venereol. 186(S):171.
3. Lu I., P. Gillieaudeau, J.A. McLane, N. Heftler, M. Kamber, S. Gottlieb, et al. 1996. Modulation of epidermal differentiation, tissue inflammation, and Tlymphocyte infilitration in psoriatic plaques by topical calcitriol. J. Cutan. Pathol. 23:419.
4. Jensen A.M., M.B. Llado, L. Skov, E.R. Hansen, J.K. Larsen and O. Baadsgaard. 1998. Calcipotriol inhibits the proliferation of hyperproliferative CD29 positive keratinocytes in psoriatic epidermis in the absence of an effect on the function and number of antigen-presenting cells. Br. J. Dermatol 139:984.
5. Kaufmann R., A.J. Bibby, R. Bissonnette, F. Cambazard, A.C. Chu, J. Decroix, et al. 2002. A new calcipotriol/betamethasone dipropionate formulation (Daivobet) is an effective once-daily treatment for psoriasis vulgaris. Dermatology 205:389.
6. Guenther L., P.C. Van de Kerkhof, E. Snellman, K. Kragballe, A.C. Chu, E. Tegner, et al. 2002. Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial. Br. J. Dermatol 147:316.
7. Douglas W.S., Y. Poulin, J. Decroix, J.P. Ortonne, U. Mrowietz, W. Gulliver, et al. 2002. A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris. Acta Derm. Venereol. 82:131.
8. Papp K.A., L. Guenther, B. Boyden, EG. Larsen, R.J. Harvima, J.J. Guilhou, et al. 2003. Early onset of action and efficacy or a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J. Am. Acad. DermatoL 48:48.
9. Kragballe K., K.L. Noerrelund, H. Lui, J.P. Ortonne, G. Wozel, T. Uurasmaa, et al. 2004. Efficacy of once-daily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris. Br. J. Dermatol. 150:1167
10. Van De Kerkhof P.C. 2004. The impact of a two-compound product containing calcipotriol and betamethasone dipropionate (Daivobet/Dovobet) on the quality of life in patients with psoriasis vulgaris: a randomized controlled trial. Br J. Dermatol. 151:663.
11. Bikowski J. 2001. The use of therapeutic moisturizers in various dermatologic disorders. Cutis 68 (S):3.
12. Loden M. 2003. Role of topical emollients and moisturizers in the treatment of dry skin barrier disorders. Am. J. Clin. Dermatol. 4: 771.
13. Petres J., I. Antal and S. Fuzesi. 1990. Klinische Erfahrugen zur Intervallbehandlung mit harnstoffhaltigen Dermatika. Z. Hautkr. 65:740.
14. Schroder W. 1983. Harnstoff und seine therapeutischen Einsatzmoglichkeiten. Fortschr. Med. 101:491.
15. Swanbeck G. 1992. Urea in the treatment of dry skin. Acta Derm. Venereol. 177(S): 7.
16. Loden M. 1996. Urea-containing moisturizers influence barrier properties of normal skin. Arch. Dermatol. Res. 288:103.
17. Stuttgen G. 1992. Ergebnisse und Konsequenzen einer langfristigen Harnstofftherapie fur die medizinische Praxis. Hautarzt 43 (S):9.
18. Traulsen J. 2004. Bioavailability of betamethasone dipropionate when combined with calcipotriol. Int. J. Dermatol. 43:611
19. van Rossum M.M., P.E. van Erp and P.C. van de Kerkhof. 2001. Treatment of psoriasis with a new combination of calcipotriol and betamethasone dipropionate: a flow cytometric study. Dermatology 203:148.
20. Vissers W.H., M. Berends, L. Muys, P.E. van Erp, E.M. de Jong and P.C. van de Kerkhof. 2004. The effect of the combination of calcipotriol and betamethasone dipropionate versus both monotherapies on epidermal proliferation, keratinization and T-cell subsets in chronic plaque psoriasis. Exp. Dermatol. 13:106.
21. Ruzicka T. and B. Lorenz. 1998. Comparison of calcipotriol monotherapy and a combination of calcipotriol and betamethasone valerate after 2 weeks' treatment with calcipotriol in the topical therapy of psoriasis vulgaris: a multicentre, double-blind, randomized study. Br. J. Dermatol. 138:254.
22. Kragballe K., L. Barnes, K.J. Hamberg, P. Hutchinson, F. Murphy, S. Moller, et al. 1998. Calcipotriol cream with or without concurrent topical corticosteroid in psoriasis: tolerability and efficacy. Br. J. Dermatol. 139:649.
23. Schopf E., J.M. Mueller and T. Ostermann. 1995. Stellenwert der adjuvanten Basistherapie bei chronisch-rezidivierenden Hauterkrankungen. Neurodermitis atopica/ Psoriasis vulgaris. Hautarzt 46:451.
24. Hagemann I. and E. Proksch. 1996. Topical treatment by urea reduces epidermal hyperproliferation and induces differentiation in psoriasis. Acta Derm. Venereol. 76:353.
25. Heydendael V.M., C.A. de Borgie, P.I. Spuls, P.M. Bossuyt, J.D. Bos and M.A. de Rie. 2004. The burden of psoriasis is not determined by disease severity only. J. Investig. Dermatol. Symp. Proc. 9:131.
26. Stern R.S., T. Nijsten, S.R. Feldman, D.J. Margolis and T. Rolstad. 2004. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J. Investig. Dermatol Symp. Proc. 9:136.